免疫原性
血凝素(流感)
流感疫苗
病毒学
重组DNA
医学
病毒
流感减毒活疫苗
甲型流感病毒
微生物学
生物
免疫学
抗体
基因
生物化学
作者
Victor C. Huber,Jonathan A. McCullers
出处
期刊:Current Opinion in Molecular Therapeutics
日期:2008-02-01
卷期号:10 (1): 75-85
被引量:6
摘要
Protein Sciences Corp and UMN Pharma Inc are developing FluBlok, an injectable trivalent influenza vaccine formulation composed of recombinant influenza hemagglutinin (HA) proteins that match the HA from the three influenza isolates that currently circulate in humans (H1N1, H3N2 and B), for the potential prevention of influenza virus infection. Phase III clinical trials to compare FluBlok and a licensed trivalent influenza vaccine for immunogenicity, safety and efficacy in preventing naturally occurring influenza are ongoing.
科研通智能强力驱动
Strongly Powered by AbleSci AI